MedeliX
Start asking

anagrelide

Xagrid · ATC code L01XX35

Also known as: Anagrelid · Brand names: Xagrid, Anagrelid +pharma, Anagrelid Aop, Anagrelid Bluefish, Anagrelid Ratiopharm, Thromboreductin, Anagrelid Abz, Anagrelid Al, Anagrelid Beta, Anagrelid Glenmark, Anagrelid Heumann, Anagrelid Hexal, Anagrelid Hikma, Anagrelid Puren, Anagrelid Zentiva …

Key facts
Active substance
anagrelide
ATC code
L01XX35
Authorisation
centrally authorised across the EU (EMA)
Dosage forms
Xagrid 0.5 mg hard capsules.
Marketing authorisation holder
Takeda Pharmaceuticals International AG Ireland
Information as of
2026-10-28

Key facts

Anagrelide is a platelet-reducing agent (phosphodiesterase III inhibitor) used to lower elevated platelet counts in essential thrombocythaemia (Xagrid, hard capsules).

What it is used for

  • Reduction of elevated platelet counts in at-risk essential thrombocythaemia patients who are intolerant to their current therapy or whose platelet counts are not reduced to an acceptable level by it.

Dosing

  • Starting dose 1 mg/day in two divided doses of 0.5 mg, maintained for at least one week.
  • Then titrate individually to the lowest effective dose that keeps platelets below 600 x 10⁹/l (ideally between 150 x 10⁹/l and 400 x 10⁹/l).
  • Dose increments must not exceed 0.5 mg/day in any one week; the maximum single dose should not exceed 2.5 mg.
  • Most patients respond adequately at 1 to 3 mg/day.
  • Elderly: no different regimen. Mild hepatic impairment or renal impairment: assess risks and benefits before starting.

Contraindications

  • Hypersensitivity to anagrelide or any excipient.
  • Moderate or severe hepatic impairment.
  • Moderate or severe renal impairment (creatinine clearance <50 ml/min).

Important warnings

  • Avoid abrupt discontinuation: risk of a sudden increase in platelet counts with potentially fatal thrombotic complications such as cerebral infarction.
  • Serious cardiovascular events (including torsade de pointes, ventricular tachycardia, cardiomyopathy, congestive heart failure); baseline ECG and echocardiography and regular monitoring; caution with risk factors for QT prolongation.
  • Correct hypokalaemia or hypomagnesaemia before starting.
  • Cases of pulmonary hypertension have been reported.
  • Regular monitoring of blood count, liver and renal function and electrolytes; not recommended if transaminases are >5 times the upper limit of normal.
  • Contains lactose.

Side effects

  • Most common: headache (approximately 14%), palpitations (approximately 9%), fluid retention and nausea (each approximately 6%) and diarrhoea (5%).
  • Serious: cardiovascular events such as torsade de pointes, ventricular tachycardia, cardiomyopathy and congestive heart failure, and pulmonary hypertension.
  • Other reactions and frequencies: see the full text.

Interactions

  • CYP1A2 inhibitors (e.g. fluvoxamine, enoxacin) could impair anagrelide clearance; CYP1A2 inducers (e.g. omeprazole) could decrease exposure.
  • Effects of other PDE III inhibitors (e.g. milrinone, enoximone, cilostazol) may be exacerbated.
  • With acetylsalicylic acid, antiplatelet effects may be enhanced; major haemorrhages have occurred.
  • Caution with medicines that prolong the QTc interval.

Pregnancy and breastfeeding

  • Not recommended during pregnancy; women of child-bearing potential should use adequate contraception.
  • Breast-feeding should be discontinued during treatment.

Summary of the official product information, written with AI on 2026-10-29. Every number was checked automatically against the original text. Not reviewed by a physician – the full official text is authoritative.

Full official text →

Common questions – ask Medelix

For patients

Package leaflet, verbatim

This product has no separate US patient information.

Authorisation and brand names by country

Medicines with exactly this active-substance composition, as listed in the national registers – alphabetical and without ranking. Whether a product is currently available is not shown here.

EU – centrally authorised (all member states)

Source: European Medicines Agency (EMA), product information

Austria

  • Anagrelid +pharma+pharma Arzneimittel Gmbh · 1 register entry
  • Anagrelid AopAop Orphan Pharmaceuticals Gmbh · 1 register entry
  • Anagrelid BluefishBluefish Pharmaceuticals Ab · 1 register entry
  • Anagrelid RatiopharmTeva B.V · 1 register entry
  • ThromboreductinAop Orphan Pharmaceuticals Gmbh · 1 register entry

Source: EMA – Article 57 product data (EU/EEA), as of 2026-10-29

Germany

  • Anagrelid AbzAbz-Pharma Gmbh · 1 register entry
  • Anagrelid AlAliud Pharma Gmbh · 1 register entry
  • Anagrelid BetaBetapharm Arzneimittel Gmbh · 1 register entry
  • Anagrelid BluefishBluefish Pharmaceuticals Ab · 1 register entry
  • Anagrelid GlenmarkGlenmark Arzneimittel Gmbh · 1 register entry
  • Anagrelid HeumannHeumann Pharma Gmbh & Co. Generica Kg, Torrent Pharma (Malta) Ltd · 2 register entries
  • Anagrelid HexalHexal Ag · 1 register entry
  • Anagrelid HikmaHikma Pharma Gmbh · 1 register entry
  • Anagrelid PurenPuren Pharma Gmbh & Co. Kg · 1 register entry
  • Anagrelid RatiopharmRatiopharm Gmbh · 1 register entry
  • Anagrelid ZentivaZentiva Pharma Gmbh · 1 register entry

Source: EMA – Article 57 product data (EU/EEA), as of 2026-10-29

Turkey

  • AnaglynARDİ FARMA İLAÇ PAZARLAMA TİC. LTD. ŞTİ. · 1 register entry
  • GraftaİLKO İLAÇ SAN.VE TİC. A.Ş. · 1 register entry
  • GrelineFARMA-TEK İLAÇ SAN. VE TİC. A.Ş. · 1 register entry
  • ThroducePHARMADA İLAÇ SAN. VE TİC. A.Ş. · 1 register entry
  • ThromboreductinAOP ORPHAN İLAÇ LTD. ŞTİ. · 1 register entry
  • XagrilynIDEOGEN İLAÇ SAN. A.Ş. · 1 register entry

Source: TİTCK – Ruhsatlı Beşeri Tıbbi Ürünler Listesi, as of 2026-10-16

Brand names in 27 more European countries
Belgium
Anagrelid Sandoz, Atremia
Bulgaria
Тромборедуктин
Croatia
Anagrelid, Atremia, Grenalvon
Cyprus
Anagrelide Aop
Czechia
Anagrelid Stada, Anagrelide Teva, Anagrelide Vipharm, Thromboreductin
Denmark
Anagrelid Bluefish, Anagrelide "stada"
Finland
Anagrelid Avansor, Anagrelid Orion, Anagrelide Sandoz, Anagrelide Stada
France
Anagrelide Arrow, Anagrelide Biogaran, Anagrelide Eg, Anagrelide Sandoz, Anagrelide Teva, Anagrelide Zentiva
Greece
Anagrelide Aop, Anagrelide Teva
Hungary
Adride, Anagrelide Stada, Anagrelide Vipharm, Thromboreductin
Iceland
Anagrelide Bluefish, Anagrelide Viatris, Xagrid
Ireland
Anagrelide Athlone Pharmaceuticals
Italy
Anagrelide Aurobindo, Anagrelide Sandoz, Anagrelide Teva
Latvia
Thromboreductin
Liechtenstein
Anagrelide Viatris, Xagrid
Lithuania
Anagrelide Teva, Thromboreductin
Luxembourg
Atremia
Malta
Anagrelide Torrent
Netherlands
Anagrelide Accord, Anagrelide Cf, Anagrelide Genthon, Anagrelide Glenmark, Anagrelide Teva
Norway
Anagrelide Bluefish, Anagrelide Viatris, Xagrid
Poland
Anagrelid Aurovitas, Anagrelide, Thromboreductin
Portugal
Anagrelida Aurovitas, Anagrelida Bluefish, Anagrelida Teva
Romania
Anagrelidă Accord, Grenalvon, Thromboreductin
Slovakia
Anagrelide Glenmark, Anagrelide Vipharm
Slovenia
Anagrelid Sandoz, Thromboreductin
Spain
Anagrelida Aurovitas, Anagrelida Bluefish, Anagrelida Glenmark, Anagrelida Pharmavic, Anagrelida Stada, Anagrelida Teva, Anagrelide Teva-Ratiopharm
Sweden
Anagrelid Accordpharma, Anagrelid Avansor, Anagrelide Bluefish, Anagrelide Glenmark, Anagrelide Sandoz, Anagrelide Stada

EMA – Article 57 product data (EU/EEA), 2026-10-29

Medelix receives no money from pharmaceutical companies. Brand names are listed alphabetically and without ranking.

Other substances in the same group

Another question about this substance?

Medelix answers clinical questions from guidelines, studies and product information – every claim with its source.

Sources

  1. European Medicines Agency. Xagrid – EPAR, Product Information. 2026-10-28. https://www.ema.europa.eu/en/documents/product-information/xagrid-epar-product-information_en.pdf
  2. EMA – Article 57 product data (EU/EEA), 2026-10-29. https://www.ema.europa.eu/en/human-regulatory-overview/post-authorisation/data-medicines-iso-idmp-standards-post-authorisation/public-data-article-57-database
  3. EMA – Article 57 product data (EU/EEA), 2026-10-29. https://www.ema.europa.eu/en/human-regulatory-overview/post-authorisation/data-medicines-iso-idmp-standards-post-authorisation/public-data-article-57-database
  4. TİTCK – Ruhsatlı Beşeri Tıbbi Ürünler Listesi, 2026-10-16. https://www.titck.gov.tr/dinamikmodul/85

Editorial: Medelix editorial team · last updated 2026-10-28 · How these pages are made · Report an error

Source: European Medicines Agency (EMA), product information. Not advertising, not a treatment recommendation. For questions about your own treatment, ask your doctor or pharmacist.